A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza

Influenza Clinical Trial

Official title:

An Adaptive Study of the Pharmacokinetics of Favipiravir in Patients With Severe

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03394209
• Other study ID #: FAVI-PK-2017001
• Status: Completed
• Phase: Phase 2
• Start date: February 6, 2018
• Est. completion date: March 27, 2019

Study information

• Verified date: May 2019
• Source: Capital Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Title: An adaptive study of the pharmacokinetics of favipiravir in patients with severe influenza Study Design: An open label, single group assignment, adaptive study to evaluate the pharmacokinetics of favipiravir in adult patients with severe influenza.

In the first stage, participants will receive favipiravir 1600mg BID on day 1, followed by favipiravir 600mg BID for 9 days.

If the proportion of patients with a minimum observed plasma trough concentration above the MEC (20μg/ml) at all measured time points after the second dose is less than 80% then a second patient cohort will be recruited and will receive favipiravir 1800mg BID on day 1, followed by favipiravir 800mg BID for 9 days.

Intervention: The 1st stage: 1600mg BID on day 1, followed with 600mg BID for 9 days. Sample size: 15 The 2nd stage: 1800mg BID on day 1, followed with 800mg BID for 9 days. Sample size: 15 Population: Males and females aged 18 years or older admitted to hospital with a positive PCR test for influenza and a PaO2/FiO2≤300mmHg or/and on mechanical ventilation for severe lung infection on admission.

Sample size 15 or 30 severe influenza patients Research hypothesis The administration of oral favipiravir at either 1600mg/600mg BID or 1800/800mg BID will result in ≥ 80% patients achieving a minimum observed plasma trough concentration above the MEC (20μg/ml) at all measured time points after the second dose.

Phase: Phase 2a, PK, safety and feasibility study. Description of Study Agent: Favipiravir (T-705) a viral RNA-dependent RNA polymerase inhibitor.

Study Duration: 1 year Participant Duration: 38 days

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: March 27, 2019
• Est. primary completion date: February 20, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Hospitalized males or females with a positive PCR test for influenza virus infection

2. Adults aged =18years

3. PaO2/FiO2=300mmHg or on mechanical ventilation

4. < 10 days since symptom onset

5. Negative pregnancy testing for childbearing age females (under 60 years)

6. Willingness to use contraception for 7 days after end of treatment

7. Informed consent

8. In addition, male subjects must:

1. Agree not to donate sperm during the study and for 7 days following the last dose of study drug, and

2. Agree to adhere strictly to one of the following contraceptive measures from the Screening Visit until 7 days after the last dose of study drug:

i. abstain from sexual intercourse or ii. have a female partner using effective means of birth control as noted below or iii. use a condom with spermicide or a second barrier method by female partner.

Female subjects

a. Of child-bearing potential must agree to adhere strictly to one of the following approved contraceptive measures during the study and for 7 days after the last dose of study drug: i. abstain from sexual intercourse or ii. have a male partner incapable of fathering a child (eg, had a vasectomy at least 6 months with history of negative semen analysis prior Screening or iii. use of one of the following methods, in combination with condom and spermicide use by a male partner: nonhormonal intrauterine device (IUD); diaphragm; or hormonal contraceptives including oral contraceptives, injectable subdermal implants, hormonal IUD, or vaginal ring b. Be unable to bear children defined as one of the following: i. absence of a menstrual period for =12 consecutive months with FSH confirmation, ii. be 60 years of age or greater, iii. had surgical removal of uterus or removal of both ovaries, or iv. had undergone tubal ligation >6 weeks prior to Day 1 dosing

Exclusion Criteria:

1. Any condition that does not allow for safely following the protocol

2. Patient refusal to accept invasive organ support treatment if needed

3. Pregnant or breastfeeding

4. Any condition resulted to reception of renal replacement therapy

5. AST > 5 times upper of limit or Child Pugh score = C

6. Serum uric acid level > 3 times upper level of normal (430 ummol/L) associated with symptoms of gout

7. Has a history of gout or is under treatment for: gout or hyperuricemia; hereditary xanthinuria; hypouricemia or xanthine calculi of the urinary tract

8. Has a history of hypersensitivity to an anti-viral nucleoside-analog drug targeting a viral RNA polymerase

9. Physician makes a decision that trial involvement is not in patients' best interest.

10. Currently or have been involved in another anti-influenza treatment trial in the last 28 days

Related Conditions & MeSH terms

• Critical Illness
• Influenza
• Influenza, Human

Intervention

Drug:
• Favipiravir
In first step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1600 mg twice daily. Starting from the second day, the dosage is 600 mg twice daily. In second step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1800 mg twice daily. Starting from the second day, the dosage is 800 mg twice daily.
• Oseltamivir 75Mg Capsule
oseltamivir will be administered at 75mg twice daily orally for 10 days

Locations

Country	Name	City	State
China	China-Japan Friendship Hospital	Beijing

Sponsors (4)

Lead Sponsor	Collaborator
Capital Medical University	Beijing Institute of Pharmacology and Toxicology, Centers for Disease Control and Prevention, China, University of Oxford

Country where clinical trial is conducted

China, 

References & Publications (7)

Dunning J, Baillie JK, Cao B, Hayden FG; International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Antiviral combinations for severe influenza. Lancet Infect Dis. 2014 Dec;14(12):1259-70. doi: 10.1016/S1473-3099(14)70821-7. Epub 2 — View Citation

Gao HN, Lu HZ, Cao B, Du B, Shang H, Gan JH, Lu SH, Yang YD, Fang Q, Shen YZ, Xi XM, Gu Q, Zhou XM, Qu HP, Yan Z, Li FM, Zhao W, Gao ZC, Wang GF, Ruan LX, Wang WH, Ye J, Cao HF, Li XW, Zhang WH, Fang XC, He J, Liang WF, Xie J, Zeng M, Wu XZ, Li J, Xia Q, — View Citation

Kile JC, Ren R, Liu L, Greene CM, Roguski K, Iuliano AD, Jang Y, Jones J, Thor S, Song Y, Zhou S, Trock SC, Dugan V, Wentworth DE, Levine MZ, Uyeki TM, Katz JM, Jernigan DB, Olsen SJ, Fry AM, Azziz-Baumgartner E, Davis CT. Update: Increase in Human Infect — View Citation

Kumar A. Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life. J Antimicrob Chemother. 2011 May;66(5):959-63. doi: 10.1093/jac/dkr090. Epub 2011 Mar 15. Review. — View Citation

Li H, Yang SG, Gu L, Zhang Y, Yan XX, Liang ZA, Zhang W, Jia HY, Chen W, Liu M, Yu KJ, Xue CX, Hu K, Zou Q, Li LJ, Cao B, Wang C; National Influenza A(H1N1)pdm09 Clinical Investigation Group of China. Effect of low-to-moderate-dose corticosteroids on mort — View Citation

Wang X, Jiang H, Wu P, Uyeki TM, Feng L, Lai S, Wang L, Huo X, Xu K, Chen E, Wang X, He J, Kang M, Zhang R, Zhang J, Wu J, Hu S, Zhang H, Liu X, Fu W, Ou J, Wu S, Qin Y, Zhang Z, Shi Y, Zhang J, Artois J, Fang VJ, Zhu H, Guan Y, Gilbert M, Horby PW, Leung — View Citation

Zheng S, Tang L, Gao H, Wang Y, Yu F, Cui D, Xie G, Yang X, Zhang W, Ye X, Zhang Z, Wang X, Yu L, Zhang Y, Yang S, Liang W, Chen Y, Li L. Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients with minimum plasma of Favipiravir trough concentration above the MEC (20µg/ml) at all measured time points after the second dose.		10 days during the intervention period
Secondary	Maximum plasma concentration observed over the treatment period (Cmax )		10 days during the intervention period
Secondary	Minimum plasma concentration observed over the treatment period (Cmin)		10 days during the intervention period
Secondary	Average pre-dose plasma concentration (Trough)		10 days during the intervention period
Secondary	Proportion of patients whose favipiravir plasma concentration at least one time exceeds MEC in study days		10 days during the intervention period
Secondary	The proportion of patients falling into each category of a five-point ordinal scale on day 10 and day 28 after starting favipiravir	The category of a five-point ordinal scale: death; hospitalised on ECMO and/or mechanical ventilation; hospitalised on supplemental oxygenation; hospitalised not on supplemental oxygenation; discharged.	28 days from starting intervention
Secondary	Duration (days) of mechanical ventilation		from reception of mechanical ventilation to ventilator weening, an average of 10 days
Secondary	Duration (days) of extracorporeal membrane oxygenation		from starting ECMO to weening, an average of 9 days
Secondary	Duration (days) of supplemental oxygenation		Duration (days) of hospitalization with oxygen therapy,an average of 13 days
Secondary	Duration (days) of hospitalization		Days from admission to discharge,an average of 19 days
Secondary	The proportion of patients with a negative RT-PCR for influenza from upper and/or lower respiratory tract samples on day 10 after starting treatment		Duration of viral shedding,an average of 15 days
Secondary	The time (days) to negative RT-PCR for influenza from upper and/or lower respiratory tract samples (capped at day 10)		Duration of viral shedding,an average of 15 days
Secondary	The proportion of patients with drug related adverse events		38 days from starting intervention
Secondary	The proportion of patients with genetic and phenotypic markers of resistance to favipiravir and/or oseltamivir		Days from admission to discharge,an average of 19 days

External Links

•   Link